Search research articles
Contact Us
Filters
Showing results (491-500 of 513) with videos related to
Page
of 52
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
March 4, 2008
The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor
John Hynes, Hong Wu, Sidney Pitt, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 28, 2015
Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of Autoimmunity
Paul R Mangan, Linhui Julie Su, Victoria Jenny, et al.
ACS Medicinal Chemistry Letters
|
December 18, 2020
Novel Tricyclic Pyroglutamide Derivatives as Potent RORγt Inverse Agonists Identified using a Virtual Screening Approach
Qingjie Liu, Douglas G Batt, Carolyn A Weigelt, et al.
ACS Medicinal Chemistry Letters
|
March 21, 2019
Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse Agonists
James J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Journal of Medicinal Chemistry
|
August 20, 2004
Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity
Ping Chen, Arthur M Doweyko, Derek Norris, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 28, 1998
The International Neuroblastoma Risk Groups (INRG): a preliminary report
R P Castleberry, J Pritchard, P Ambros, et al.
Journal of Medicinal Chemistry
|
September 12, 2015
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase Inhibitor
Chunjian Liu, James Lin, John Hynes, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 9, 2016
Identification and synthesis of potent and selective pyridyl-isoxazole based agonists of sphingosine-1-phosphate 1 (S1P1)
Junqing Guo, Scott H Watterson, Steven H Spergel, et al.
Journal of Medicinal Chemistry
|
March 1, 2016
Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based Series
Scott H Watterson, Junqing Guo, Steve H Spergel, et al.
Journal of Medicinal Chemistry
|
February 16, 2021
Tricyclic-Carbocyclic RORγt Inverse Agonists-Discovery of BMS-986313
Michael G Yang, Myra Beaudoin-Bertrand, Zili Xiao, et al.
Page
of 52
Search research articles
Search
Showing results (491-500 of 513) with videos related to
Sort By:
Page
of 52
Bioorganic & Medicinal Chemistry Letters
|
March 4, 2008
The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor
John Hynes, Hong Wu, Sidney Pitt, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 28, 2015
Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of Autoimmunity
Paul R Mangan, Linhui Julie Su, Victoria Jenny, et al.
ACS Medicinal Chemistry Letters
|
December 18, 2020
Novel Tricyclic Pyroglutamide Derivatives as Potent RORγt Inverse Agonists Identified using a Virtual Screening Approach
Qingjie Liu, Douglas G Batt, Carolyn A Weigelt, et al.
ACS Medicinal Chemistry Letters
|
March 21, 2019
Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse Agonists
James J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Journal of Medicinal Chemistry
|
August 20, 2004
Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity
Ping Chen, Arthur M Doweyko, Derek Norris, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 28, 1998
The International Neuroblastoma Risk Groups (INRG): a preliminary report
R P Castleberry, J Pritchard, P Ambros, et al.
Journal of Medicinal Chemistry
|
September 12, 2015
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase Inhibitor
Chunjian Liu, James Lin, John Hynes, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 9, 2016
Identification and synthesis of potent and selective pyridyl-isoxazole based agonists of sphingosine-1-phosphate 1 (S1P1)
Junqing Guo, Scott H Watterson, Steven H Spergel, et al.
Journal of Medicinal Chemistry
|
March 1, 2016
Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based Series
Scott H Watterson, Junqing Guo, Steve H Spergel, et al.
Journal of Medicinal Chemistry
|
February 16, 2021
Tricyclic-Carbocyclic RORγt Inverse Agonists-Discovery of BMS-986313
Michael G Yang, Myra Beaudoin-Bertrand, Zili Xiao, et al.
Page
of 52